Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Completed · Phase 1/Phase 2

Conditions studied: Prostate Cancer

In brief

The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of ODM-201 in patients with castrate resistant prostate cancer.

Key facts

Study ID
NCT01317641
Run by
Orion Corporation, Orion Pharma
People needed
136
Starts
2011-03-01
Expected to finish
2013-07-01
Last updated by the study team
2017-03-29

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.